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The formation and persistence of surface-attached microbial communities, known as
biofilms, are responsible for 75% of human microbial infections (National Institutes of
Health). Biofilm lifestyle confers several advantages to the pathogens, notably during
the colonization process of medical devices and/or patients’ organs. In addition, sessile
bacteria have a high tolerance to exogenous stress including anti-infectious agents.
Biofilms are highly competitive communities and some microorganisms exhibit anti-
biofilm capacities such as bacterial growth inhibition, exclusion or competition, which
enable them to acquire advantages and become dominant. The deciphering and control
of anti-biofilm properties represent future challenges in human infection control. The
aim of this review is to compare and discuss the mechanisms of natural bacterial
anti-biofilm strategies/mechanisms recently identified in pathogenic, commensal and
probiotic bacteria and the main synthetic strategies used in clinical practice, particularly
for catheter-related infections.
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INTRODUCTION
Biofilms are multimicrobial communities enclosed in self-synthetized polymeric matrices, attached
to biotic or abiotic surfaces. Eighty percent of the world’s microbial biomass are found in the biofilm
state, and sessile cells are thus considered as the predominant mode of life for microorganisms
in nature. These cells frequently express phenotypes different from their non-adherent planktonic
counterparts, with a high capacity to colonize new surfaces and a high tolerance to exogenous stress
(Donlan and Costerton, 2002; Macfarlane and Dillon, 2007). Depending on the microbial species
and their localization (environmental/biomedical/industrial), biofilms can be either beneficial
or detrimental for humans. According to the National Institutes of Health, more than 75%
of microbial infections that occur in the human body are promoted by the formation and
persistence of biofilms. Some bacterial biofilms, such as the intestinal microbiota, also play
protective and functional roles. Intestinal commensal and beneficial bacteria–bacteria interactions
are directly involved in host homeostasis (Wrzosek et al., 2013). In human health, an imbalance
of microbiota, called dysbiosis, is associated with several diseases (Martín et al., 2014a). This
correlation is in part due to bacterial interplay between members of bacterial communities
such as group effect, cooperation, kin competition, genetic expression profiles, and phenotypic
diversification (Rendueles and Ghigo, 2015) that could be encompassed by the adjective “anti-
biofilm”. Interference interactions have already inspired the design of alternatives to antibiotics
in the fight against pathogenic microorganisms (Rasko and Sperandio, 2010). Recently, major
challenges and opportunities in this field were addressed during the workshop “Biofilms, Medical
Devices, and Anti-Biofilm Technology” (Phillips et al., 2015). Many medical device-associated and
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persistent infections can be attributed to biofilm-associated
microbes. To tackle the overarching public health issue of the
contribution of biofilms to health care-associated infections it
was suggested that clinicians and health care workers should
be more closely involved in their detection and treatment.
It was also suggested that the applied science of biofilm
formation and prevention would provide greater knowledge
of the contamination of medical devices. Some answers are
to be found in the development of the anti-biofilm activities
of beneficial microbes and/or the understanding and diversion
of the anti-biofilm capacities of pathogenic bacteria. In this
review, after establishing a definition of the term anti-biofilm,
we will focus on bacterial anti-biofilm activities with examples
of probiotic and pathogenic bacteria. With reference to clinical
examples, we will then discuss the use, challenges and limitations
of anti-biofilm strategies.
ANTI-BIOFILM ACTIVITY: WHAT DOES IT
MEAN?
Biofilms were initially defined as structured communities of
bacterial cells enclosed in self-produced polymeric matrices
and adherent to inert or living surfaces (Costerton et al.,
1999). Later, it became obvious that biofilms exhibit altered
phenotypes compared with corresponding planktonic cells,
especially with regard to gene transcription (Lindsay and von
Holy, 2006). Biofilms are ubiquitous and nearly all species of
microorganisms, bacteria, fungi, yeasts, algae, protozoa, and
viruses are able to adhere to surfaces and/or to each other to form
biofilms (Wingender and Flemming, 2011). Biofilms formed
by pathogenic bacteria are the most extensively documented,
such as Klebsiella pneumoniae biofilms seen in Figure 1 on
abiotic (1A) and biotic surfaces (epithelial cell monolayer;
1B). Biofilms are increasingly recognized by the public health
community as an important source of pathogens (Donlan and
Costerton, 2002; Wingender and Flemming, 2011). They are
involved in specific infectious diseases such as osteomyelitis,
otitis media, peridontitis, and dental caries (Costerton et al.,
1999) and in chronic diseases such as pulmonary infections of
cystic fibrosis patients. They are also involved in nosocomial
infections due to opportunistic pathogens, especially urinary
tract, lower respiratory tract, and surgical site infections and
bacteremia, and mostly when invasive medical device are
being used. In 2012, a prevalence survey of 1,938 healthcare
facilities and 300,330 patients carried out by the French
association RAISIN “Réseau d’alerte, d’investigation et de
surveillance des infections nosocomiales” showed that the most
frequent microorganisms associated with nosocomial infections
(RAISIN, 2015) were Escherichia coli, Staphylococcus aureus
(38.1% resistant to methicillin, MRSA), Pseudomonas aeruginosa,
and K. pneumoniae, all of which are high biofilm producers
(Figure 1C).
Biofilms pose significant clinical problems because sessile
bacterial cells are inherently recalcitrant to antimicrobial
agents such as antibiotics (for review, Lebeaux et al., 2014).
Several factors are responsible for the biofilm-associated
resistance, including the density and the physiological state
of the cells, but also the physical structure of the biofilm.
Exopolysaccharides and extracellular DNA (eDNA) of the biofilm
matrix can act as a barrier to diffusion and thus reduce
penetration of antibiotics into biofilms. The effectiveness of
this barrier varies between antibiotics; tetracyclines, rifamycins,
fluoroquinolones, and daptomycin penetrate better than beta-
lactams, aminoglycosides, and glycopeptides (Stewart et al.,
2009; Singh et al., 2010; Cha et al., 2011; Doroshenko et al.,
2014). The effects of antibiotics can also be affected by the
particular microenvironment of biofilm, such as acidic pH and
low level of oxygen encountered in the deep layers of the
aggregates (Siala et al., 2014). The cells within biofilm are
generally less metabolically active than planktonic cells and
therefore significantly less sensitive to mechanism of action
by many antimicrobials targeting synthesis of macromolecules
or metabolic pathways such beta-lactams and quinolones (Xie
et al., 2005; Mascio et al., 2007). In addition, a percentage of
cells within biofilm may be persister cells, which are transiently
antibiotic tolerant without harboring genetic changes seen in
antimicrobial resistance. The presence of antibiotics can per
se induce persistence (Dörr et al., 2010; Kwan et al., 2013)
and/or enhance biofilm formation, particularly at sub-Minimal
FIGURE 1 | Four-hour-old biofilm of Klebsiella pneumoniae. (A) scanning electron microscopy (SEM) observation of the biofilm formed on Thermanox slide
performed as previously described (Goncalves et al., 2014). (B) Confocal microscopic observations of the biofilm (green) formed onto A549 pulmonary cell
monolayer stained with Phalloidin (red) and DAPI (blue). Observations were performed as previously described (Marquès et al., 2015). (C) Relative percentage of the
most frequent micro-organisms associated with nosocomial infections in France (adapted from RAISIN, 2015).
Frontiers in Microbiology | www.frontiersin.org 2 April 2016 | Volume 7 | Article 592
fmicb-07-00592 April 25, 2016 Time: 18:26 # 3
Miquel et al. Strategies for Biofilm Prevention and Control
Inhibitory concentrations (MIC) (Wang et al., 2010b; Kaplan
et al., 2012; Ng et al., 2014; Lázaro-Díez et al., 2016) and
thus lead to treatment failure. The in vitro determination of
MICs is restricted to planktonic cells growing exponentially
under conditions that are optimal for action of the drug but
unlikely to be met in biofilm populations. In vitro and in vivo
experiments demonstrated that the MIC and the minimum
bactericidal concentration (MBC) for biofilm bacterial cells are
usually much higher (approximately 10–10,000 times) than their
counterpart planktonic cells (Hengzhuang et al., 2012; Marquès
et al., 2015). The effective antibiotic MBC in vivo for biofilm
eradication are therefore impossible to reach by conventional
antibiotic administrations due to the toxicities and the side effects
of antibiotics and the limitation of renal and hepatic functions.
Combination of antibiotics with different killing mechanisms
leading to synergism remains nowadays the best solution for
the treatment of biofilm infections. Rifampicin and fosfomycin-
based combinations have shown in vitro enhanced activities
against biofilm embedded Staphylococcus aureus isolates (Tang
et al., 2012, 2013) but their in vivo efficiencies still remain to be
determined (Table 1).
In addition, biofilm phenotype provides resistance to host
defenses, in particular, leukocyte phagocytosis. There are various
possible mechanisms of action by which bacteria escape from the
immune system including inhibition of inclusion of biofilm cells
by phagocytes (Günther et al., 2009) and low immunogenicity
of the biofilm matrix (Thurlow et al., 2011). These resistance
properties and the genetic and phenotypic versatilities of cells
within biofilm prompted workers to look for biofilm-specific
therapies to eradicate this common cause of persistent infections.
The term “anti-biofilm” appeared in the literature during the
1990s and is now widely used without, however, being fully
defined. On the basis of current knowledge, this review proposes
the use of the term anti-biofilm as “a natural or induced process,
leading to reduction of bacterial biomass through the alteration
of biofilm formation, integrity and/or quality”.
Studies have shown that two different anti-biofilm
mechanisms are able to modulate biofilm formation: inhibition
of bacterial surface attachment and destabilization/disruption
of mature biofilms irreversibly attached. Many of the existing
anti-biofilm agents are non-biocidal, but some bactericidal
molecules could be considered as anti-biofilm agents as they
are still active against mature biofilms protected by their
architecture. Bactericidal anti-biofilm agents should be very
specifically targeted otherwise their use could impair the
composition of established ecosystems and damage beneficial
microbiota. Nevertheless, anti-biofilm strategies represent
interesting approaches for medical biotechnology as attested by
the large number of recent publications (Rumbaugh and Ahmad,
2014). Anti-biofilm agents fall into two large groups, synthetic
and natural (Table 2). Synthetic biofilm inhibitors, in part listed
below, are mostly derived from bactericidal technologies.
Non-thermal Plasma (NTP) Technology
Plasma is a unique state of matter that results from a rapid
ionization of the gas obtained through subjecting gas to
extremely high temperatures or passing gas through high-voltage
electricity (Scholtz et al., 2015). The unspecific character of
TABLE 2 | The different classes of anti-biofilm agents.
Synthetic Natural product
Non-thermal plasma Antibiotics
Photodynamic substances Protozoan grazing
Nanoparticles Plant products
Surface topographic modifications Bacteriophages
Other peptides and molecules Microbial agents
TABLE 1 | Effects of different antibiotics family against Staphylococcus biofilms.
Antibiotic Species Assay Effect on biofilm Reference
Beta-lactams Penicillins and most
cephalosporins
Staphylococcus
aureus
in vitro Induction of biofilm formation at Sub-MICs Ng et al., 2014
Kaplan et al., 2012
Lázaro-Díez et al., 2016
Ceftaroline Bactericidal anti-biofilm activity after prolonged exposure Landini et al., 2015
Rifampicin S. aureus in vitro Anti-biofilm activity, synergistic with fusidic acid and tigecycline Tang et al., 2013
S. epidermidis High anti-biofilm activity alone or in combination with vancomycin or
daptomicin
Olson et al., 2010
Vancomycin S. aureus in vitro Promotion of biofilm formation through an autolysis-dependent
mechanism
Hsu et al., 2011
S. epidermidis Induction of eDNA release at sub-MICs leading to increased biofilm
formation
Doroshenko et al., 2014
Daptomycin S. aureus in vitro Induction of viable but non-cultivable cells in biofilm at low
concentrations
Pasquaroli et al., 2014
Anti-biofilm effect in monotherapy LaPlante and
Woodmansee, 2009
in vivo Prevention of the emergence of rifampin resistance mutants Cirioni et al., 2010
Fosfomycin S. aureus in vitro Anti-biofilm activity synergistic with linezolid or minocycline or
vancomycin
Tang et al., 2012
eDNA, extracellular DNA; MIC, minimal inhibitory concentrations.
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their anti-microbial activity, low toxicity for human tissues
and absence of long-living toxic compounds make non-thermal
plasmas (NTPs) a very promising tool for biofilm prevention and
control in the decontamination of foods and biological materials
(Ermolaeva et al., 2015).
Photodynamic Substances
To produce an antimicrobial photodynamic therapy (PDT),
three major components are needed, light, oxygen, and a
photosensitizer. The excitation of the photosensitizer by light
generates reactive oxygen species (ROS), which leads to the
oxidation of biomolecules of microorganisms and results in
cell damage and death (Hamblin and Hasan, 2004). It was
recently shown that the photosensitizer 5-aminolevulinic acid
(5-ALA), once absorbed by proliferating bacteria, is converted
into the natural photosensitizer Protoporphyrin IX (PpIX), which
has synergic effects with the antibiotic gentamicin against the
biofilm of several Gram-positive bacteria (Barra et al., 2015). For
example, photoactive TiO2 antibacterial coating was proposed to
reduce pin tract infections and proved to have antibacterial effect
against Staphylococcus strains (Villatte et al., 2015).
Nanotechnology
Two kinds of nanotechnologies can affect biofilm formation
on a surface. First, nano-modifications of surface topography
(roughness and nanostructure) limit primary bacterial adhesion
without the use of any biocide molecules (Desrousseaux et al.,
2013). However, results on their efficacy have been conflicting
and inhibition of primary adhesion seems to be dependent mostly
on the spatial organization of the nano features. Second, surfaces
can be chemically modified by addition of nanoparticles made
of iron, silver, zinc, or titanium (Neethirajan et al., 2014). Most
of these nanoparticles exert antibacterial activity by interacting
electrostatically with the bacterial membrane, which leads to
membrane disruption (Beyth et al., 2015). In addition, the
bioavailability of these nanoparticles due to their high surface-
to-volume ratios allows them to penetrate a mature biofilm
and thus to target bacterial cells not only at the surface but
also within the deep layers of biofilm (Bakkiyaraj and Pandian,
2014).
Other molecules could be added to this list, in particular
detergents and antiseptics and synthetic peptides (de la Fuente-
Núñez et al., 2014). However, the increasing interest in promoting
health by natural means has concentrated research trends on
natural biofilm inhibitor products with less biocidal activity.
Protozoan Grazing
Protozoan grazing is believed to be the major trophic pathway
whereby the biomass produced by bacteria, cyanobacteria
and algae re-enters the food web. However, this type of
microorganism’s biomass control is hard to adapt to human
health. In vitro, the ciliate Colpoda maupasi has been shown
to reduce the thickness of mature biofilms of opportunistic
pathogens formed by Klebsiella pneumoniae, Pseudomonas
fluorescens, and Staphylococcus epidermidis (Huws et al., 2005). In
addition, the presence of protozoa in drinking water distribution
systems can regulate the autochthonous and allochthonous
bacterial populations (Sibille et al., 1998), which suggests that this
process could be used to decrease or limit nosocomial infections
caused by environmental contamination.
Plant Products
Plants represent a huge resource of bioactive molecules. A recent
study showed that some of them contain anti-biofilm compounds
that inhibit growth, interrupt quorum sensing (QS) and/or
prevent bacterial adhesion (Husain et al., 2015). Garlic acts
as a QS-interfering compound in the treatment of bacterial
infections, owing to the production of ajoene, a sulfur-rich
molecule (Jakobsen et al., 2012). Cranberry is also an anti-
adhesion agent (Allison et al., 2000; Cai et al., 2014) able to
prevent urinary infections (Rafsanjany et al., 2015), dental caries
(Girardot et al., 2014), and skin infections (Morán et al., 2014).
Bacteriophages
The most abundant category of microorganisms on earth,
are viruses whose interactions with biofilm members are
ecologically important in horizontal gene transfer between
bacteria (transduction). Bacteriophages play other important
roles in microbial communities such as the modulation of
bacterial populations. They also produce a number of enzymes
able to disrupt the protection afforded by the biofilm matrix,
thereby modifying biofilm architecture and increasing its
susceptibility to antibiotics (Abedon, 2015). However, there
are several drawbacks to the use of phages: (i) phage lytic
activity releases Gram-negative bacterial-membrane-endotoxins,
(ii) phage-resistant bacteria can arise rapidly (Örmälä and
Jalasvuori, 2013) and (iii) phages can spread bacterial virulence
genes (Rossmann et al., 2015).
Bioinspired anti-biofilm molecules can be isolated from
eukaryotes, such as the lactoferrin (Ammons and Copié, 2013),
but most are derived from microbial phenomena occurring
within the biofilms themselves. In fact, bacterial fitness within
biofilm relies on the ability of a given strain not only to adhere,
settle, and develop as a biofilm, but also to inhibit others from
doing so (Rendueles and Ghigo, 2015).
BACTERIAL-DERIVED BIOFILM
INHIBITORS
Intra- and interspecies interactions and competition between
microorganisms within biofilm are governed by ecological
and evolutionary parameters (Rendueles and Ghigo, 2015).
Bacterial interferences are present at different levels of
biofilm development; they can affect primary adhesion and/or
maturation via exclusion/competition phenomena, modify
matrix composition or enhance dispersal. Bacterial anti-biofilm
activities govern microbe–surface interactions and microbe–
microbe interactions and they are shared by commensal,
pathogen, and probiotic bacteria (Figure 2). The increasing
interest in promoting a natural approach to health has intensified
research in the field of probiotics worldwide over the last two
decades. Probiotics, recently redefined by an expert panel of the
International Scientific Association for Probiotics and Prebiotics
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FIGURE 2 | Schematic representation of the impact of bacterial
anti-biofilm activities on microbe-surface interactions and on
microbe-microbe interactions.
(ISAPP) as “live microorganisms that, when administered in
adequate amounts, confer a health benefit on the host” (Hill et al.,
2014), have gained increasing medical attention because of their
antagonist effects against numerous pathogens. Probiotics with
anti-biofilm properties, especially Lactobacilli, seem promising
in the treatment of oral, wound and vaginal infections in both
clinical trials and in vitro studies (Vuotto et al., 2014). For some
probiotics, this beneficial activity is boosted when grown as
biofilm (Rieu et al., 2014). Pathogens also exhibit anti-biofilm
properties when competing with other bacteria to reach new
ecological niches.
Effect on Growth
Most beneficial and pathogen bacteria are able to secrete
antibacterial substances such as antimicrobial peptides (AMPs),
lantibiotics, bacteriocins, microcins, lactic acid, and hydrogen
peroxide. Using different mechanisms of action, such as
membrane permeabilization and interference with essential
enzymes, these molecules inhibit bacterial growth or cause
bacterial death. Some of them are highly effective against sessile
cells such as the bacteriocins, nisin A, lacticin Q, sonorensin,
and colicin R (Okuda et al., 2013; Rendueles et al., 2014;
Chopra et al., 2015). Interestingly, colicin R produced by
the commensal Escherichia coli ROAR029 strain, preferentially
targets sessile rather than planktonic bacteria (Rendueles et al.,
2014). The enhanced sensitivity of sessile cells to colicin R has
been attributed to a reduced growth rate caused by diminished
turnover of outer membrane components or increased stress
within the biofilm. Several bacteriocin-producing strains have
filed patent application for food and biomedical applications
(Benmechernene et al., 2013). Interestingly, the probiotic
lactobacilli strains Lactobacillus casei Shirota and L. rhamnosus
HN001 inhibited growth and biofilm formation of the pathogen
Streptococcus mutans by producing an acid environment and
bacteriocin-like polypeptides, suggesting the synergic properties
of these two mechanisms of action (Lin et al., 2015). Anti-
biofilm agents impairing bacterial growth usually display narrow
spectra. For instance, AMPs have shown a considerably stronger
antimicrobial activity against biofilm formed by Gram-positive
bacteria than by Gram-negative strains, justifying their potential
use in the specific treatment of ocular infections, which are mostly
due to Gram-positive bacteria (Dawgul et al., 2014).
Alteration of Initial Adhesion by Surface
Modification
The most effective strategy to antagonize the first step of
biofilm formation is the use of biosurfactants and bioemulsifiers
able to modify the physicochemical cell surface properties and
thus to impair microbial adhesion. This is illustrated notably
by the production of Pseudomonas aeruginosa rhamnolipids,
which are able to disrupt the cohesiveness of biofilm formed
by Bordetella bronchiseptica (Irie et al., 2005), Bacillus subtilis,
S. aureus, and Micrococcus luteus (Quinn et al., 2013). Another
anti-biofilm biosurfactant is the surfactin produced by Bacillus
subtilis, which is able to reduce colonization of surfaces by the
food pathogenic bacteria Listeria monocytogenes, Enterobacter
sakazakii, and Salmonella enteritidis (Nitschke et al., 2009). Other
pathogenic bacteria share such mechanisms: K. pneumoniae and
the uropathogenic strain E. coli CFT073 exhibit a broad-spectrum
anti-biofilm non-bactericidal activity by secreting extracellular
polysaccharide (EPS) with anti-adhesion properties (Valle et al.,
2006; Goncalves et al., 2014). EPS are the essential building blocks
for the biofilm matrix of most microorganisms but they can
also inhibit their neighbors’ biofilm structuration by interfering
with initial adhesion, dispersion, cell-to-cell communication,
and/or matrix formation (Rendueles and Ghigo, 2012). One
example of this type of anti-biofilm mechanism of action is
the interference of the capsular polysaccharides of Actinobacillus
pleuropneumoniae serotype 5 with cell-to-cell and cell-to-surface
interactions of other bacteria, which prevents them from forming
or maintaining biofilms (Karwacki et al., 2013). More examples
are given in the review of Rendueles and Ghigo (2012), in which
the authors advise that targeting surface colonization rather than
overall bacterial fitness is a more promising approach.
Homeostatic relations between the hosts and their microbiota
considered as biofilms at the surface of epithelial host
cells are abundant. At the intestinal level, commensal and
probiotic bacteria strengthen intestinal barrier function by
enhancing mucin production and tight junction integrity, and by
modulating the activity of the immune system. These properties
are assimilated to biotic surface modifications involved in
the reduction of pathogenic-associated biofilm and thus the
protection of the host from infections. For instance, the probiotic
mixture VSL#3 is able in vivo to induce mucin gene expression
(Caballero-Franco et al., 2007) and commensal bacteria such as
bifidobacteria or Bacteroides thetaiotaomicron promote defense
functions of the host epithelial cells via the production of acetate
(Fukuda et al., 2012; Wrzosek et al., 2013). In contrast to these
adaptations of host capacities, bacteria can specifically target
the degradation of host receptors and then inhibit the adhesion
process. For instance, some S. epidermidis strains secrete a serine
Frontiers in Microbiology | www.frontiersin.org 5 April 2016 | Volume 7 | Article 592
fmicb-07-00592 April 25, 2016 Time: 18:26 # 6
Miquel et al. Strategies for Biofilm Prevention and Control
protease named Esp, which degrades human receptor proteins
(e.g., fibronectin, fibrinogen, and vitronectin) recognized by
S. aureus and involved in host-pathogen interaction and tissue
colonization (Sugimoto et al., 2013).
Modulation of Biofilm Quality and
Integrity
Evidence has shown that anti-biofilm bacterial agents not
only modify biotic and abiotic surfaces but also alter the
physical properties of bacterial surfaces involved in cell-to-cell
aggregation and surface attachment processes. For instance, EPS
released by L. acidophilus A4 exert anti-biofilm activity against
a wide range of Gram-positive and Gram-negative bacteria by
affecting the expression of genes involved in curli production and
chemotaxis, and thus modifying cell-to-cell (autoaggregation)
and cell-to-host cell (adhesion) adherence (Kim et al., 2009).
More recently, inhibition of S. aureus was shown to be due to
the physicochemical properties of the Lactobacillus cells surface
such as hydrophobicity, autoaggregation, and coaggregation
abilities (Ren et al., 2012). These kinds of inhibition processes
are likely induced by alteration of the expression of key
surface structures that are required for surface colonization and
govern the complex interactions between pathogenic and/or
common environmental bacteria. For instance, Streptococcus
intermedius down-regulates the expression of both short (mfa1)
and long (fimA) fimbriae required for attachment and biofilm
development by Porphyromonas gingivalis (Christopher et al.,
2010). The anti-biofilm activity of the oral strain of Streptococcus
does not affect growth rate and is mediated by the surface
arginine deiminase ArcA. More recently, it was shown that
Lactobacilli strains impair fungal biofilm formation structure
by down-regulating the expression of Candida glabrata EPA6
and YAK1 genes, encoding, respectively, an adhesin involved in
the yeast biofilm development and its transcriptional regulator
(Chew et al., 2015).
Anti-biofilm activities are characterized by inter-species
communications not only between different genera of
prokaryotes but also between prokaryotic and eukaryotic
cells. Bacterial anti-biofilm activities are therefore likely
to naturally regulate bacterial populations in an ecological
niche. For example, the Esp protease secreted by a subset of
commensal S. epidermidis in the nasal microbiota inhibit biofilm
formation by pathogenic S. aureus (Iwase et al., 2010). Ecological
homeostasis of polymicrobial biofilms involves exclusion,
competition and displacement phenomena between pathogenic,
commensal and/or probiotic bacteria for adhesion/attachment
sites and/or nutriment access. A new mechanism of invasion
resistance deployed by oral-derived microbial community (O-
mix) to defend their domains was recently reported. The O-mix
is able to restrict the colonization of exogenous E. coli strains by
sensing the E. coli lipopolysaccharides (LPS) and subsequently
killing them with oxygen free radicals (He et al., 2010). The
underlying molecular mechanisms were recently discovered
and involve the coordinated role of three commensal bacterial
species (Staphylococcus saprophyticus, Streptococcus infantis,
and Streptococcus sanguinis) acting as ‘Sensor,’ ‘Mediator,’ and
‘Killer,’ respectively (He et al., 2014). Numerous in vitro studies
have shown that Lactobacilli can exert competitive exclusion
of different pathogenic bacteria such as S. aureus, Salmonella
enterica, Shigella sonnei, E. coli, and Gardnerella vaginalis by
interfering with their binding sites on the epithelial cell surface
(Jankowska et al., 2008; Prince et al., 2012; Zhang et al., 2012;
Abedi et al., 2013; Castro et al., 2013).
Anti-biofilm activity can modulate biofilm bacterial diversity
via interferences between species or between bacteria and the
host surface. Different mechanisms of action can explain the
chain reaction leading to the anti-biofilm process, the first of
which is modification of cell-to-cell communication. The search
for anti-biofilm compounds acting on QS and/or on signal
molecule of targeted bacteria has already been undertaken (Leoni
and Landini, 2014). For a recent review on QS inhibitors, see
Brackman and Coenye (2015). It must, however, be noted that
jeopardy of bacterial communication can lead to dispersion of
a wide range of bacterial biofilms, and induction of biofilm
dispersal by fatty acid signals may be a commonly used
mechanism. For instance, the cis-2-decenoic acid produced by
P. aeruginosa induces dispersion of P. aeruginosa PAO1 biofilm
but also of those formed by a variety of Gram-negative and
Gram-positive bacteria (E. coli, K. pneumoniae, Proteus mirabilis,
Streptococcus pyogenes, Bacillus subtilis, S. aureus, and Candida
albicans; Davies and Marques, 2009). Many bacterial enzymes
involved in active biofilm dispersal have also been identified,
in particular those involved in matrix degradation such as
the serine protease Esp and the deoxyribonuclease I, DNase I.
However, the most studied biofilm-matrix-degrading enzyme is
dispersin B (Kaplan, 2009; Iwase et al., 2010; Brown et al., 2015).
This glycoside hydrolase produced by the periodontopathogen
A. actinomycetemcomitans completely inhibits biofilm formation
and disperses preformed biofilm of several bacterial species:
E. coli, S. epidermidis, S. aureus, P. fluorescens, and Yersinia pestis
(Kaplan et al., 2004). As a consequence of the destruction of the
physical integrity of the highly protective matrix barrier, sessile
microbial cells are suddenly exposed to the external offensive
of both antibiotics and innate host immune defenses (Kaplan,
2009). To avoid potential adverse effects due to the release of live
bacteria from biofilms it seems essential to combine molecules
with biofilm dispersing activity and anti-bacterial activity: cis-
2-decenoic with antibiotics or disinfectants for eradication of
catheter-associated biofilms (Rahmani-Badi et al., 2014; Sepehr
et al., 2014) and dispersin B with KSL-W antimicrobial peptide
for treatment of chronic wound infections (Gawande et al.,
2014).
SUCCESSFUL USE OF ANTI-BIOFILM
METHODS IN HUMAN HEALTH
Clinical trials performed with beneficial bacteria and particularly
probiotics make use of exclusion and/or inhibition of growth
of pathogens to protect the mucosa from the colonization of
these undesirable microorganisms (Martín et al., 2014b). These
strategies can be considered as anti-biofilm strategies, since
aggregates formed on biotic surfaces, such as epithelia, have
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molecular properties similar to those of biofilms formed on
abiotic surfaces and are actually considered as such (Stacy et al.,
2016). However, most molecular knowledge of the biofilm mode
of life derives from studies performed on aggregates formed
on abiotic surfaces, and a lot remains to be discovered about
the specific biofilm host-immune response. Most anti-biofilm
based randomized clinical trials have focused on infections
associated with biofilm formation on abiotic surfaces: medical
devices (especially ventilator-associated pneumonia and catheter-
related infections) or dental surfaces. In these randomized clinical
trials, the main strategy used to successfully control biofilm
formation was the use of surface-coated (Berra et al., 2008;
Kollef et al., 2008) or surface-treated catheters (Scannapieco
et al., 2009; Quintas et al., 2015) and/or changes in surface
composition of the device (Ghorbanzadeh et al., 2015). The
last paragraph of this review will focus on these different
strategies, with special emphasis on their advantages and
limitations.
THE CASE OF CATHETER-RELATED
INFECTIONS
Central venous catheters are essential in the management
of patients and they are commonly used for the intravenous
administration of fluids, blood products, complex drug
treatments and total parenteral nutrition, for monitoring
hemodynamics and for hemodialysis provision. The major
concern with their use is colonization by microorganisms,
which subsequently leads to infection, mostly catheter-related
bloodstream infections (CRBSIs). CRBSIs are potentially
devastating, entailing substantial morbidity, mortality and
additional healthcare costs. It is estimated that a total of 250,000
cases of CRBSI occur yearly in the USA (Maki et al., 2006).
Catheter luminal colonization is the first step in catheter
infection. In catheters with placement shorter than 21 days
(short-term catheters), colonization originates mainly from the
skin microbiota, with the microorganisms migrating distally
along the external surface into the subcutaneous catheter tract.
The microorganisms can also seed the intraluminal catheter
surface from contaminated hubs, connectors and infusates. The
intraluminal source of infection may be especially important in
patients with long-term hemodialysis catheterization. Microbes
colonizing catheter lumens constitute with host proteins a biofilm
in which they proliferate and escape systemic antibiotics and
immune host defenses. Ultimately, microorganisms can detach
from biofilm and invade the bloodstream causing CRBSI and
metastatic infections.
Multifaceted infection control interventions including
maximal barrier precautions, line care bundle, development of
educational programs, outcome surveillance and performance
feedback of infection control practices have been implemented
and succeeded in decreasing CRBSI rates. Several other
preventive measures undertaken to further reduce the risk of
CRBSI have been developed including coating catheter surfaces
with antimicrobial agents and locking catheter lumens with
antimicrobial solutions.
(1) Coating catheter with anti-infective agents (antiseptics
or antibiotics) aims at inhibiting bacterial adhesion to
the catheter lumen surface and preventing biofilm growth
and subsequent infection. Catheters can be bonded to
the inner and/or outer surface or impregnated within the
material itself. The most commonly used antimicrobial
agents are chlorhexidine-silver sulphadiazine (CHSS) and
minocycline–rifampicin (MR).
First-generation antiseptic catheters whose outer surface was
impregnated with CHSS had a lower rate of CRBSI when inserted
for a short duration (<8 days) in units with a high incidence of
CRBSI (>3 per 1,000 catheter-days; Walder et al., 2002). Second-
generation CHSS catheters were then developed, with a long
half-life of impregnation at the internal and external surfaces.
Their use decreased the rate of catheter colonization but failed to
diminish the incidence of CRBSI in units with acceptable rates
of CRBSIs (Timsit et al., 2011). The development of bacterial
resistance in relation to the use of CHSS catheters has never
been observed in a clinical setting, but resistance to chlorhexidine
has been detected in experimental studies (Tattawasart et al.,
1999). Physicians must be aware that in rare cases hypersensitivity
reactions have been reported in patients who were inserted with
these catheters (Trautner and Darouiche, 2004).
Catheters impregnated intraluminally and extraluminally
with MR have been widely developed. MR concentrations
on the surface of these catheters decrease with placement
duration but still exert antimicrobial activity through 60 days
of catheterization (Darouiche et al., 2005). Their use is
associated with a decrease in the rates of colonization and
infection compared with standard catheters and first-generation
CHSS impregnated catheters (Hockenhull et al., 2009; Wang
et al., 2010a). No prospective trial has compared second-
generation CHSS and MR-impregnated catheters. In a recent
published retrospective study, second-generation CHSS and MR-
impregnated catheters, in comparison with standard catheters,
decreased the risk of CRBSI to a similar extent (Lorente et al.,
2015).
There are concerns regarding the potential of MR-
impregnated catheters for altering the microbiologic profile
of catheter colonization/infection and promoting bacterial
resistances. Data indicate that they can enhance the risk of fungal
catheter colonization (León et al., 2004; Picioreanu et al., 2004;
Lardon et al., 2011). However, bacterial resistance induced by
the prolonged use of MR-impregnated catheters has not been
demonstrated in clinical studies (Ramos et al., 2011; Bonne et al.,
2015).
Other catheter materials have been tested including oligon,
silver, carbon, platinum, and antimetabolite. Several prospective,
randomized studies comparing these catheters with un-coated
catheters in the prevention of catheter colonization and infection
have yielded conflicting results (Kalfon et al., 2007; Walz et al.,
2010; Lai et al., 2013).
Current evidence suggests the magnitude of the effect of
antimicrobial-impregnated catheters differs according to the type
of patient population. For instance, their beneficial benefit was
mainly observed in critically ill patients and only inconsistently in
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cancer patients and in patients receiving total parenteral nutrition
(Lai et al., 2013). The decision to use these catheters should be
based on a risk benefit analysis taking into account the incidence
of CRBSI observed in the institution for at-risk populations and
balancing the attributable costs of CRBSI, the price over cost
of impregnated catheters and concerns for the emergence of
bacterial resistance.
Antimicrobial-impregnated catheters should be reserved for
patients whose catheter placement is expected to be longer than
5 days, in units with unacceptable rates of infections (more than
three CRBSIs per 1,000 catheter-days), despite adherence to a
comprehensive preventive strategy (Bach et al., 1996).
(2) The antimicrobial lock (AML) strategy is designed to
prevent or to treat endoluminal catheter infections. It
is intended for catheters that are not used continuously
and consists of instilling a selected AML solution into
the catheter lumen while the catheter is idle. The AML
solution is allowed to dwell or is “locked” for a certain
period of time in the catheter lumen. Thereafter, the lock
solution is aspirated and discarded or flushed through the
catheter into the bloodstream. This strategy can achieve
local antimicrobial concentrations 100–1,000 times higher
than that obtained by parenteral treatment to overcome the
adaptive bacterial resistance of sessile bacteria.
An ideal AML solution should possess several important
properties including widespread bactericidal activity against the
microorganisms commonly involved in CRBSIs, the potential
to penetrate biofilm and kill sessile cells, prolonged chemical
stability that does not impair catheter integrity, a low potential
for promoting antimicrobial resistance, a low risk of toxicity and
adverse events, and the ability to maintain catheter patency by
preventing catheter occlusion and thrombosis. Thus, most AML
solutions combine anticoagulant and anti-biofilm activities.
A wide variety of antibiotics have been used alone or in
combination to lock catheter lumen, including penicillins,
cephalosporins, aminoglycosides, fluoroquinolones, folate
antagonists, glycopeptides, lipopeptides, oxazolidinones,
rifampicin, polymyxins, tetracyclines, glycylcyclines, and
carbapenems. The antibiotic solution is currently mixed
in unfractionated heparin (UFH) to obtain antimicrobial-
anticoagulant solutions. However, there is a growing body
of data supporting the use of alternative anticoagulants such
as low molecular weight heparins, calcium chelators (citrate
or ethylenediamine-tetra-acetic acid [EDTA]), and tissue
plasminogen activator. The choice of antibiotics and their
concentration is based on the expected susceptibility of biofilm
to the antimicrobials and their ability to kill the biofilm cells.
In addition, the decision to choose a mixture must take into
account the results of studies conducted on the stability and
compatibility of the solution, which depend on the type
of agents combined, their respective concentration and the
experimental conditions including temperature, exposure
duration, and storage conditions. Experimental studies suggest
that antibiotic UFH mixtures are compatible with a broad
range of antibiotic concentrations when unfractionated heparin
concentration is higher than 3500 U/mL, while precipitation
occurs when antibiotics are diluted with unfractionated heparin
at concentrations lower than 1000 U/mL (Droste et al., 2003).
Numerous data are now available to guide physicians in the
choice of antibiotic lock solution components and their final
concentrations (Mermel et al., 2009; Justo and Bookstaver,
2014).
The widespread use of the prophylactic antibiotic lock strategy
raises concerns in clinical practice because of the risk for
the development of antimicrobial-resistant organisms (Landry
et al., 2010; Dixon et al., 2012). Emerging gentamicin resistant
bacteria have been identified as causative agents of bacteremia
in chronic hemodialysis patients when tunneled catheters were
prophylactically locked with a solution of gentamicin (4 mg/mL)
and unfractionated UFH (5000 U/mL; Landry et al., 2010). In
addition, catheter locking may induce severe adverse events when
a fraction of the lock solution spills from the catheter lumen into
the bloodstream during and after instillation (Agharazii et al.,
2005). Detectable gentamicin serum levels have been observed in
chronic dialysis patients receiving preventive gentamicin-citrate
lock (Dogra et al., 2002). Severe neurological disorders have been
reported after prolonged exposure to aminoglycoside-based lock
solution (Dogra et al., 2002; Saxena et al., 2002). The use of
prophylactic antibiotic lock solution with antibiotics routinely
used to treat systemic infections remains debatable, and in our
opinion should therefore be discouraged.
One way to reduce the likelihood of antibiotic resistance
is the use of catheter lock solutions that do not include an
antibiotic component. The most commonly used non-antibiotic
lock solutions are taurolidine, a high concentration of citrate or
of EDTA and ethanol.
– Taurolidine is an amino acid taurine derivative with a broad-
spectrum activity against bacteria and fungi. It acts as a
disinfectant by inducing irreparable microbial cell wall injury
(Willatts et al., 1995). Several randomized control studies have
compared taurolidine and UFH lock solutions in preventing
CRBSI (Betjes and van Agteren, 2004; Bisseling et al., 2010;
Solomon et al., 2010; Dümichen et al., 2012; Handrup
et al., 2013) and yielded mixed results depending on the
study population. In pediatric oncology patients and infants
on home parenteral nutrition, taurolidine used at various
concentrations (1.35 and 2%) with or without addition of 4%
citrate decreased the rate of CRBSI as compared to low doses
of unfractionated heparin (150 and 100 U/mL; Bisseling et al.,
2010; Dümichen et al., 2012; Handrup et al., 2013). In contrast,
in hemodialysis patients, the use of 1.35% taurolidine – 4%
citrate solution failed to prevent CRBSI and exit site infections
as compared to UFH lock solution (5,000 U/mL), but increased
the need for premature catheter removal for poor flow (Liu
et al., 2014; Zhao et al., 2014).
– Citrate and EDTA have anticoagulant activities similar to
those of heparin by chelating ionized calcium, which results
in a blockade of the coagulation pathways. In addition, they
enhance the activity of antimicrobial drugs and therefore there
is a growing interest in the use of cationic chelator-based lock
solutions in the prevention of CRBSI. These lock solutions
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have been widely studied and have been demonstrated to be
highly effective in hemodialysis patients and pediatric cancer
patients (Zacharioudakis et al., 2014; Zhao et al., 2014). In
hemodialysis patients, the mixture of 7.0% sodium citrate,
0.15% methylene blue, 0.15% methylparaben, and 0.015%
propylparaben reduced the risk of CRBSI in a randomized
open label trial (Maki et al., 2011) but citrate alone was not
more effective than UFH (Zhao et al., 2014). A similar result
was observed with a lock solution of 4% EDTA (Kanaa et al.,
2015). In addition, there have been concerns about the use of
citrate at high concentrations owing to its potential toxicity,
allergic reactions, arrhythmia and cardiac arrest (US Food and
Drug Administration, 2000).
– Ethanol is an inexpensive antiseptic that acts by non-specific
protein denaturation. It has drawn much interest as a lock
solution for the prevention of CRBSI because it exerts
bactericidal and fungicidal activity against a broad range of
microorganisms and is unlikely to promote antimicrobial
resistances. The time required by ethanol to eradicate
experimental biofilm varies according to the microorganisms
studied and is concentration-dependent. Ethanol has no
antithrombotic properties and cannot be mixed with UFH
because of potential precipitation. Randomized control studies
on ethanol locks at concentrations higher than 70% v/v in the
prevention of CRBSI have yielded conflicting results because
of differences in study design, case mix population, and lock
dwell time (Sanders et al., 2008; Slobbe et al., 2010; Broom
et al., 2012; Pérez-Granda et al., 2014; Souweine et al., 2015).
Either way, there are a number of concerns with the use of
such high concentrations of ethanol in lock solutions for fear of
catheter structural degradation, plasma protein precipitation
and catheter occlusion (Mermel and Alang, 2014). However,
ethanol solution at a 40% v/v concentration inhibits bacterial
and fungi growth in established biofilms, does not induce
catheter damage, and has satisfactory compatibility when
mixed with low molecular weight heparin and heparinoids.
When combined with low molecular weight heparin, 40% v/v
ethanol may exert strong anticoagulant activity and has only a
marginal impact on plasma protein precipitation. No clinical
study has so far assessed the efficacy of such mixtures in
preventing CRBSI.
FUTURE CHALLENGES AND
LIMITATIONS OF ANTI-BIOFILM
STRATEGIES
Conventional and current anti-biofilm therapies target one
bacterial species without considering that most biofilm-related
and chronic infections are due to the persistence of polymicrobial
biofilms (Hall-Stoodley and Stoodley, 2009). Thus, there is
no ideal solution to totally eradicate biofilm, but the key
would be the simultaneous application of agents implementing
mechanisms with synergic potential in order to both disturb
the biofilm structure and kill bacteria (Khan et al., 2014).
Multidisciplinary approaches are needed to decipher the generic
networks underlying complex community interactions and to
place them in their ecological and evolutionary context. The
use of computational tools to comprehensively understand
anti-biofilm processes seems essential. Biofilm and multispecies
biofilm modeling techniques are available and take into
account heterotroph parameters (Picioreanu et al., 2004; Lardon
et al., 2011). Three-dimensional computer models of biofilm
dynamics have been developed as tools for investigating
mechanisms of protection against antimicrobial agents in
biofilms (Chambless et al., 2006). They could be used for the
analysis of the effects of anti-biofilm agents, in particular to
assess their efficacy and to consider how they could impact the
emergence of new classes of resistant microbes (Phillips et al.,
2015).
The Food and Drug Administration (FDA) has received
several medical device submissions that contain anti-biofilm
claims (Phillips et al., 2015). However, current in vitro and
in vivo assays are unable to effectively predict biofilm outcomes
in humans and it is therefore important to develop reliable
alternatives to clinical studies for the evaluation of anti-biofilm
claims with standardized anti-biofilm procedures and validation
methods that can establish correlation with clinical outcomes.
That goes hand in hand with the elucidation of the mechanisms
of action of the numerous anti-biofilm and bactericidal agents
described so far. As already proposed in the Nutrition and
Health claims domain, considering bacterial anti-biofilm agents
will be useful in the future to establish a framework to help
academic and industrial communities to explore their potential
in accordance with health and nutrition policy (Miquel et al.,
2015). In part because of the administrative complexity of these
approaches, other potential applications must be envisaged such
as vaccine strategy. The vaccine against the oral bacterium
Fusobacterium nucleatum that preferentially targets FomA, an
outer membrane protein involved in bacterial co-aggregation,
can be considered as a pioneer anti-biofilm vaccine (Liu et al.,
2010). New and specific vaccines are needed but it is necessary
first to more fully investigate the interactions between biofilm
and the host immune system, a domain as yet unexplored (Bryers,
2008).
Finally, modification of gene expression of pathogens within
biofilm by probiotic counterparts could represent an interesting
anti-biofilm approach with a dual-purpose: to limit bacterial
colonization and inhibit the expression of virulence factors.
For instance, some Lactobacilli down-regulate the expression
of the virulence genes of S. mutans, S. aureus, and Salmonella
enterica (Das et al., 2013; Nouaille et al., 2014; Wu et al.,
2015). In the literature, the biofilm mode of life is generally
opposed to the virulence capacities of bacteria (Claret et al.,
2007), suggesting that biofilm ensures that bacteria stay within a
specific niche and that its destabilization induces adverse effects.
Further studies are required to assess the in vivo benefit of anti-
biofilm approaches that can guarantee to have therapeutic or
prophylactic benefits and to be very specific, highly effective
and environmentally safe. However, due consideration should be
given to the comparative risks and benefits for the patient, in
particular the potential side effects on beneficial bacteria of the
host microbiota and the emergence of antimicrobial resistances
(Phillips et al., 2015).
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CONCLUSION
The objective of the review was to give a better definition of
the anti-biofilm activities involved in microbial crosstalk. The
prevalence of biofilm is not only a significant problem for human
health, but also in food and the food industry, and in water and
sewage treatment, and warrants expenditure for the development
of effective anti-biofilm strategies. Coating catheter surfaces
with antimicrobial agents and locking the catheter lumens with
antimicrobial solutions are two different approaches that have
produced encouraging results with regard to catheter-related
infections. A major obstacle will be to translate the use of original
anti-biofilm agents into commercial reality, in part because of
the necessity to develop specific drug delivery applications. It
still remains a real challenge for scientists in this innovative
cross-cutting research domain.
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